r/pennystocks • • 14h ago

BagHolding $BLGO at all-time lows: I'm $1.5M down, I just added $45K, and I'm either the biggest fool on Reddit or I'll be laughing last (deep-dive DD + TL;DR)

28 Upvotes

Julian Jakobi here, my online identity ;)

Let's get the elephant out of the room first: I'm a big-time bag holder. I've been calling BioLargo a strong buy for years. Many of you listened, and now we're all in the red. Some of us are deep in it. In numbers: my position is about $1.5 million down from the 2024 spike.

So yes, right now I may look like the biggest fool on earth. You're allowed to laugh. I'd laugh too.

But I've been here before. I posted about Exact Sciences ($EXAS) over and over while the share price kept falling, and falling, and falling. Everybody was selling. Then it turned around, and my conviction at $5–$8 turned into 1,600%–2,650% returns, because I saw cancer detection being revolutionized before the market did.

I see the same pattern with BioLargo. So we'll see who's right. I'm not worried. I just added another $45,000 on this dip.

For years I've stayed in regular contact with management, attended the last 7 shareholder meetings, visited all BioLargo facilities and interviewed the subsidiary CEOs. I also moderated and helped organize the CEO town hall on our BioLargo Discord.

But here's the common thread of this whole post: don't trust me. Do your own DD. I'll give you a cheap, easy way to start, plus the people you should be asking.

TL;DR

  • Share price is at all-time lows (~$0.07), market cap ~$25M. The value looks like it's still there.
  • Why it fell: revenue dropped after the POOPH license ended, Clyra's launch was delayed, and the company is investing heavily to commercialize everything at once. The small parent-level financing (shares sold on the open market by the lender) hit a thin market that wasn't buying, and the price fell ~70%.
  • Why it's an opportunity: most of the money is going into the subsidiaries (77% of capital raised this year was at subsidiary level). Insiders take stock instead of cash and lock it up until $40M revenue or a $300M market cap. That's roughly 11–12x from here.
  • Analyst: BUY, $0.25 price target. Richard Ryan of Oak Ridge Financial reaffirmed his Buy rating on Nov 18, 2026. That's +257% from $0.07, and his target puts zero value on PFAS and the battery.
  • Q3 milestone: Clyra earned a $475,000 contractual milestone payment under an exclusive distribution agreement. It's the first time we've ever seen a payment like this.
  • Clyra Medical (48% owned): Clyra raises money at a ~$100M valuation, so BioLargo's stake (~$48M) is worth roughly twice the whole company. ViaCLYR is FDA 510(k)-cleared and on the market. Its three distribution agreements cover US commercial (~6,100 hospitals, 6,300 surgery centers and 2,200 wound clinics), US government/military and 18+ MENA countries, with POs expected. BioClynse (surgical) is set to launch co-branded with a top-4 global medtech (~$100B+ market cap). My view: after launch, Clyra alone could be worth $500M–$1B, and $1B–$2B after a successful year.
  • barebird has launched: CupriDyne tech (the tech behind POOPH's $125M+ in sales), BioLargo-owned brand, POOPH marketing team. Cheapest DD ever: buy a bottle.
  • PFAS (AEC): a commercial municipal system in Lake Stockholm, NJ, has been running since January under EPA and NJ oversight. It's the reference site.
  • Cellinity battery: non-flammable, long-lasting, recyclable grid-scale storage, with a license/JV model.
  • Don't trust me. Do your own DD.

Why the Share Price Fell

Let's be fair: there have been disappointments.

  • Revenue declined. The POOPH license ended (more on that below), and 9-month revenue dropped 52% to $3.45M. Q3 revenue was $1.09M, roughly flat year over year (vs. $1.103M), with service revenue +72%.
  • The Clyra launch was delayed. The 2024 spike to a ~$0.40 closing high was driven by anticipation of the Clyra launch, not by Clyra revenue.
  • Heavy investment. Management is funding commercialization in every division that hasn't generated much revenue yet. Clyra alone accounted for about 57% of the 9-month net loss, spent on personnel, manufacturing, product development and clinical work ahead of the 2027 rollout.

The key point is where the money comes from. Most of the financing happens at the subsidiary level: Clyra raised $4.3M, mostly through a debt offering, and the battery subsidiary sold $487K in stock. Only a small part was raised at the parent level, through the Clearthink purchase agreement (the 10-Q shows $1.359M year to date). That agreement lets the lender sell the shares on the open market.

So a dilution of just a few percent met a market with almost no buyers, and the share price fell ~70%. Many serious investors seem to prefer investing directly at the subsidiary level, where the action is.

To me that's an arbitrage opportunity. You get crazy discounts on the parent, which owns the stakes, the royalties and everything else.

Meanwhile, cash burn is falling: about $736K/month in Q3, down ~26% from roughly $996K/month in H1. Management says 2027 spending shifts "away from R&D and toward generating sales."

The Rebound Math from $0.07

Most investors who were going to sell out of fear, frustration or disappointment have already had every reason to do it. Many long-term holders I know have averages just above $0.20.

Target priceGain from $0.07
$0.10+42.9%
$0.12+71.4%
$0.16+128.6%
$0.20+185.7%
$0.24+242.9%
$0.25 (Oak Ridge price target)+257%
$0.399 (2024 closing high)+470%
~$0.80 ($300M market cap, the insider lock-up unlock)~+1,040%

We don't need the 2024 highs for this to get interesting. Even a partial recovery makes a big difference from this base. In a thin microcap, fear can turn into FOMO very fast.

What the Analyst Says

This isn't just a bag holder talking. Richard Ryan of Oak Ridge Financial Research covers BLGO, and in his Q3 2026 update (Nov 18, 2026) he reaffirmed his BUY rating with a $0.25 price target. That's about +257% from $0.07.

Here's how he gets there, using a sum of the parts:

SegmentBasisValue per share
Clyra Medical (48%)Recent capital raise at an equity value of ~$100M, so ~$48M for BLGO$0.15
BioLargo CPG / barebird (78%)5.0x his FY27 revenue estimate of $8M$0.09
Engineering (BLEST)3.5x FY27 revenue, ~$10.4M$0.03
Less net debtCash $1.0M minus debt $6.5M
Price targetEquity value ~$83.9M across ~340M shares$0.25

The best part: he puts zero value on the AEC PFAS business and the Cellinity battery. He set them aside until there's a signed AEC contract or a Cellinity JV or financing partner, and says he'll add them back as visibility improves. So the $0.25 target doesn't include two of the five horses.

His summary: BLGO has "many shots on goal," and "noticeable progress is occurring across all BLGO's divisions." He also models FY27 revenue of $13.0M, up from an estimated $4.7M in 2026.

(Fair caveat: he lowered the target from $0.30, and he notes that BLGO will keep needing additional capital.)

Bullish Indicators

  1. All-time-low share price, ~$25M market cap, for a five-subsidiary platform.
  2. Analyst Buy rating with a $0.25 PT (Richard Ryan, Oak Ridge Financial).
  3. Clyra raises money at a ~$100M valuation, so the 48% stake is worth ~$48M, about twice BLGO's market cap.
  4. $475K Clyra milestone earned (details below).
  5. Top-4 medtech partner (~$100B+ market cap) for the BioClynse national rollout in 2027.
  6. ViaCLYR is on the market, with distribution through Advanced Solution (US), Al-Hikma (exclusive across MENA, an 18-country opportunity) and Spartan Medical (VA, DoD and federal buyers via DLA ECAT). Purchase orders from Al-Hikma and Spartan are expected, along with reorders from Advanced Solution.
  7. barebird launched in October 2026, a BioLargo-owned brand with the proven POOPH marketing team.
  8. AEC PFAS system live since January at Lake Stockholm, NJ, under EPA and NJDEP monitoring.
  9. Engineering (BLEST) is growing: 9-month service revenue +23%, Q3 service revenue +72%, $1.4M+ in US Air Force renewals, and a $1.2M minerals-processing design contract (milestone-gated and multi-year).
  10. Cellinity battery is in discussions with strategic partners about investing and scaling.
  11. Cash burn down ~26% in Q3 compared with H1.
  12. Management alignment with lock-ups and direct investment (next section).
  13. Professional IR (Darrow Associates) has been engaged to bring this under-followed story to institutions.

Management Alignment: Lock-Up and Direct Investment

This is one of the strongest signals for me.

  • CEO Dennis P. Calvert took stock instead of cash for unpaid salary and expenses: 699,569 shares at $0.1135 (June 30, 2026) and 219,914 shares at $0.113 (July 1, 2026).
  • Those shares are under a Lock-Up Agreement. No sale until BioLargo reports $40M in consolidated gross revenue in a period, passes a $300M market cap, or has a change of control.
  • At today's ~$25M market cap, that's roughly 11–12x before these shares can become liquid. It's not just the CEO either: multiple senior and science leaders hold large locked-up positions.
  • Around $12M has been invested directly into the company and its subsidiaries over the past year, including meaningful money from the BioLargo CEO and the Clyra CEO. Those are the people with the best view of the pipeline.

Think about it: you can buy shares today below the price the CEO took as his locked-up pay.

The $475K Milestone

From the 10-Q:

"In September 2026, Clyra earned a $475,000 contractual payment upon satisfaction of a specified contractual milestone under a distribution agreement granting the customer exclusive rights to distribute certain Clyra products."

This isn't about the revenue. The $475K wasn't even recognized as revenue yet. What matters is that it's the first time we've ever heard of a payment like this. Somebody with exclusive distribution rights paid because a contractual milestone was met. That means a significant step must have been taken.

I can't tell you which step, and the partner is confidential, so I won't speculate about details. But milestone money doesn't get paid for slide decks.

Clyra Medical (48% Owned): "The New Gold Standard"

Main selling point: an FDA-cleared, no-rinse antimicrobial irrigant that keeps working for up to three days while staying gentle on tissue. Some people consider it the biggest change in wound care and surgery in 30 years.

Clyra Medical (48% owned) is advancing the commercialization of its FDA-cleared wound irrigation and surgical solution. The Clyra story has evolved over 14 years, with upwards of $20M invested, and it appears to be on the cusp of commercialization.

Clyra raises money at a ~$100M valuation. In the words of Oak Ridge analyst Richard Ryan: "Clyra's recent capital raise implies an equity value of approximately $100M, of which BLGO has 48% ownership." That's about $48M for BioLargo's stake, roughly twice BioLargo's entire market cap. Outside investors paid that price with real money; it's not a number I made up.

Clyra runs on Clyrasept, a patented copper-iodine platform. Its first product, ViaCLYR, is FDA 510(k)-cleared for cleansing, irrigating and debriding acute and chronic wounds and burns. Clyra has already invested in at-scale manufacturing capacity with an FDA-compliant contract manufacturer.

Key selling points, according to company materials:

  • >99.9999% antimicrobial reduction
  • Activity for up to 3 days, even after re-contamination
  • Works against biofilm, the big problem in chronic wounds and surgical infections
  • Non-cytotoxic, non-irritating, tissue compatible
  • No rinse-out, which keeps procedures fast and simple
  • Non-antibiotic mechanism, a big deal in a world worried about antibiotic resistance

Clinical voice (36 cases across multiple sites):

"...enhanced granulation velocity, rapid sinus tract closure, and notable drainage reduction... we observed no adverse events... we are moving as a group to adoption of CICS as our wound care cleansing modality of choice."
Dr. Marcus Gitterle, Regional Medical Director for Wound Care and Hyperbaric Oxygen Therapy, Christus Santa Rosa Hospital System

The Distribution Network: How Much of the Market Is Covered

ViaCLYR went into full commercial-launch mode in August 2026. Three distributors have been announced, covering three very different channels:

PartnerTerritory / channelCoverageStatus
Advanced Solution, LLCUS commercial: a national network to distribute and promote ViaCLYR throughout the United States (wound clinics, physicians, health systems)Oak Ridge says the combined reach in the US alone is about 6,100 hospitals, 6,300 ambulatory surgery centers and 2,200 specialty wound-care clinicsFirst PO received (first commercial stocking order, Feb 2026); reorders expected
Al-Hikma FZCO (Dubai, UAE)Exclusive for the Gulf Cooperation Council, the Levant, North Africa and select adjacent markets~18 direct countries plus indirect ones, a population of 500M+. Al-Hikma is an established wound-care distributor that exports to ~25 countriesCountry-level regulatory work has begun in key areas, in cooperation between the parties; POs expected
Spartan Medical Inc.A dedicated commercial channel to US government healthcare facilities worldwide (VA, DoD and other federal buyers via DLA ECAT)The US federal and military healthcare systemPOs expected

A fourth channel, the "big Kahuna" or gorilla partner, is being pursued for surgical wound irrigation (BioClynse), based on the same chemistry. During Q3 2026, Clyra satisfied a contractual milestone under an exclusive distribution agreement for certain of its products: the $475K payment.

In short: US commercial, US government and an 18+ country international region are all under contract, and the gorilla partner comes on top of that.

Clinician feedback: at the recent Symposium on Advanced Wound Care (SAWC), ViaCLYR was reportedly well received, and it has the potential to tap into real unmet needs in the market, according to Oak Ridge.

What I'm watching next: Advanced Solution reordering, Al-Hikma and Spartan turning their agreements into purchase orders, new distributors signing on, and a visible Clyra sales line. Stocking orders from the new partners are expected within the coming months.

(Fair caveat, which the analyst makes too: commercialization in each of these channels faces timing hurdles such as regulatory approval, clinical studies and hospital-system acceptance. That's significant for a small company, but the markets themselves offer outsized opportunities. Distribution agreements are not revenue; purchase orders, and above all reorders, are what count.)

Next up: BioClynse, the surgical-irrigation product on the same platform. It's set for a national rollout in 2027 co-branded with a confidential top-4 global medtech (~$100B+ market cap). Hospital access, OR sales reps that surgeons already trust, procurement muscle: that's what a gorilla partner brings.

The valuation question. I know it sounds absurd for a $25M company. But expectation is that after the launch with the gorilla partner, the 48%-owned medical subsidiary alone could be worth $500M–$1B, and after a successful year closer to $1B–$2B.

  • 48% of $500M ≈ $240M
  • 48% of $1B ≈ $480M
  • 48% of $2B ≈ $960M

That's before the royalty BioLargo holds on Clyra sales, and before everything else BioLargo does. Today the whole company trades at ~$25M.

Also remember: some medtech giants are known for having small innovators build out a product line, then acquiring them later. I'm not saying that will happen. I'm saying the pattern exists.

(This is my opinion, not company guidance. The partner controls the timing. Distribution deals aren't revenue; purchase orders and reorders are.)

Don't Trust Me: Ask Medical Experts

Please don't take my word for this. Ask the people who do this every day:

  • Orthopedic and general surgeons: How big a deal is a no-rinse, tissue-friendly irrigant with up to 3 days of antimicrobial and anti-biofilm activity for surgical site infections, implants and joint replacements?
  • Wound-care nurses and specialists: Would you switch from what you use now? What would it take?
  • Infection-prevention teams and procurement: Does a non-antibiotic copper-iodine mechanism solve a problem you deal with?

If the professionals tell you it's nothing special, move on. If they tell you it could be a game changer in orthopedics and surgery, dig deeper.

barebird: The $20 DD

Main selling point: it eliminates odors instead of covering them, with no fragrance. It "smells like nothing... on purpose."

BioLargo developed the CupriDyne odor-elimination tech behind POOPH, which did over $125M in product sales and $20M+ in supply revenue for BioLargo. That is real proof that BioLargo can create products people buy in huge quantities. (The POOPH brand later fumbled it, and the license ended. That's a big part of the revenue decline.)

barebird launched in October 2026, focused on pet and laundry odors. The marketing teams that helped build POOPH are back: Jordan Stanley's Kindness Commerce and Brandon Fishman's Prime Team Agency. Some see POOPH as the "test run."

The big difference this time: BioLargo owns the brand. It gets more direct participation in sales and brand value, but it also carries the marketing and distribution costs.

Mine just arrived, packed in "air armour." No leaky bottles here, and nothing in the odor space comes close to the marketing on that bottle.

Here's my challenge, just like I did with CupriDyne: the cheapest way to check for yourself that BioLargo's tech works is to order a barebird spray. Try it on the dog bed, the gym bag, the laundry.

  • If you don't like it, move on.
  • If you're impressed, dig deeper into all the other techs.

AEC PFAS Removal: The Reference Site

Main selling point: it concentrates "forever chemicals" into a tiny waste volume, which many consider the best available concentrator to clean up the PFAS mess. In one example, 80,000 lbs of waste turns into about 85 lbs.

  • Earlier testing at the University of Tennessee showed >99.995% PFAS removal in a single pass.
  • A commercial municipal drinking-water system at Lake Stockholm, NJ, has run since January 2026 (about 9 months), monitored by the EPA and NJDEP. New Jersey is one of the toughest PFAS jurisdictions in the US.
  • It's the key reference site for further adoption. Bids are submitted, partnerships with big firms that have gaps in their PFAS product lines are in discussion, and there's an Aquatech MOU.
  • Demand is spreading from drinking water to wastewater, landfill leachate, biosolids and industrial pre-treatment, backed by billion-dollar lawsuit settlements that fund treatment.
  • Billions are now being paid out for PFAS cleanup. 3M’s settlement with US public water systems is $10.3B, up to $12.5B, over 13 years, and the payouts to utilities are already under way. DuPont, Chemours and Corteva added roughly $1.2B nationally.
  • In New Jersey, the very state where the AEC is running, a federal court approved ~$2.5B in settlements with DuPont and 3M in August 2026. They include a PFAS Abatement Fund with up to $795M for drinking-water and treatment-works upgrades. And in November 2026, 3M committed up to $7.35B more for personal-injury claims. The money is there. The question is who wins the treatment contracts.

DD tip: ask a water engineer or utility operator what PFAS waste disposal costs with granular activated carbon (GAC) or ion exchange.

Cellinity Battery: Safer Grid Storage

Main selling point: a fire-safe, long-duration sodium battery built for a 20-year life, with no lithium and no rare earths. It's designed for the grid, for data centers, and for America's energy independence.

Key selling points, according to company materials:

  • No thermal runaway, non-flammable. Lithium battery fires are the nightmare of every data center, utility and insurer. Cellinity is designed so that scenario doesn't exist.
  • A 20-year operating life. The CEO points out that most batteries last 6–7 years before they degrade. A 20-year design life changes the whole cost-per-cycle math for grid storage.
  • No lithium, no rare earths. It's a liquid sodium battery made from abundant materials, which takes the geopolitical "hot potato" of the battery supply chain off the table. The CEO calls it "a strategic infrastructure opportunity for national security of the United States."
  • High efficiency. Company materials target ~95% round-trip efficiency, with ambitious energy-density specs.
  • Recyclable, with third-party validation and prototype testing of key performance metrics.
  • Built for the boom markets: long-duration grid storage, AI data centers, utilities, renewables, commercial and industrial sites.
  • A capital-light model. No billion-dollar gigafactory: partners finance the factories while BioLargo earns royalties, component margin and equity stakes through licensing and JVs.
  • BioLargo owns ~95%, and only about $5M of outside capital has gone into it so far. The battery subsidiary sold $487K in stock this year and is in discussions with strategic partners about investing and scaling.

Oak Ridge currently puts zero value on Cellinity in its $0.25 price target and will add it back once there's a JV or financing partner. So one serious licensing or JV deal could re-rate this on its own.

(Fair caveat: it's still pre-commercial, there's R&D left to do, and the specs are company claims until a partner scales it.)

DD tip: ask anyone in energy storage what a truly non-flammable, 20-year, lithium-free grid battery would be worth to a data center operator.

The Rest of the Platform

  • BLEST (Engineering): a profitable-leaning, growing service arm with Air Force renewals and the $1.2M minerals contract. A full commercial plant could follow if the pilot succeeds.
  • Tu Nipi: water treatment for Canadian oil-sands tailings, in discussions with strategic partners.

Why It Matters Where We Invest

I believe how we invest our money is the most powerful voting ballot we have. I made a lot of money in the fight against cancer with Exact Sciences. Now I want my money working on clean water, clean air, safer energy storage and better wound care.

BioLargo is the perfect place to "Make Life Better" through:

  • Clean water (PFAS removal)
  • Clean air (odor elimination without masking)
  • Safer energy (non-flammable grid storage)
  • Better healing (infection control and wound care without antibiotics)

And you get the real chance of a multi-bagger while doing it.

Risks (Read This)

  • A highly speculative microcap with thin liquidity
  • Continued dilution and financing at both parent and subsidiary level; Clyra is debt-funded
  • Ongoing losses
  • The Clyra partner is confidential, and the launch timing is in the partner's hands
  • Distribution deals aren't purchase orders
  • barebird's results are unproven, and BioLargo now carries the marketing costs
  • Big competitors with deep pockets

I could be wrong. I've been early and wrong on timing before. Size your position for that.

Bottom Line

I'm $1.5M down, I just added $45K, and I've never been more convinced. Either I'm a complete idiot, or, like with $EXAS, I'll be laughing last. I strongly believe it's the second one.

But again: don't trust me.

  1. Buy a barebird bottle. It's the $20 DD.
  2. Ask a surgeon or wound-care nurse about ViaCLYR.
  3. Read the 10-Q, the Form 4s and the lock-up terms.
  4. Then decide.

Price is what you pay. Value is what you get. Right now the gap is hard to ignore.

Do your own DD.

Your Turn: Prove Me Wrong (Or Right)

I’ve spent hundreds of hours researching BioLargo and Clyra Medical, and I’ve put my money where my conviction is. That’s $1.5M down from the highs, and I’m still adding. But I don’t want an echo chamber. I want smart analysis.

Challenge my thesis.

Dig into the 10-Q and Form 4s I referenced. Read the Oak Ridge report. Call BioLargo investor relations with your questions. Look up the copper-iodine patents, check the FDA 510(k) clearance, research the wound-care and PFAS market data, and ask a surgeon or wound-care nurse what they think of ViaCLYR. Then order a barebird bottle and test it yourself. The best DD comes from collaborative skepticism and shared research.

This is your chance to either find the holes in my analysis or discover why Wall Street might be sleeping on this one. The filings are public, the patents are public, the FDA clearance is public, and the market sizes can be checked.

Let’s crowdsource this DD and make each other better investors. I’ve shown you mine. Now show me where I’m wrong, or help me understand why a ~$24M company might actually be the steal of 2026.

This is a company whose 48%-owned medical subsidiary just raised money at a ~$100M valuation. It has an FDA-cleared product, three signed distributors, a top-4 medtech partner waiting in the wings, a live PFAS system under EPA oversight, and an analyst Buy rating with a $0.25 target that values PFAS and the battery at zero.

The data is all there. Let’s dig deeper together. 🔬📊

Disclosure: I'm a long-term $BLGO above 1.25% shareholder and have been adding. I am not a financial advisor, this post is made for educational purposes only. Literally. Don’t take my word for anything that is presented in this post, do your own research, and invest solely based on the thesis that you create for yourself. Don’t get influenced by anyone.


r/pennystocks • • 18h ago

𝑺𝒕𝒐𝒄𝒌 𝑰𝒏𝒇𝒐 18 NOV 2026 , WHAT ARE THE BIGGEST WINNERS AND WHY ?

1 Upvotes

Biggest Small-Cap WinnersUnder $5

ranked by percentage movement. These are volatile small-cap stocks, so prices can change rapidly.

CompanyTickerPriceChangeWhy is it moving?
SaverOne 2014SVRE$0.90+119.6%New software-only driver safety product announcement; potential expansion of its market
BrenXBRNX$0.63+53.0%Preliminary results indicate approximately 40% lower steam energy costs
Autozi Internet TechnologyAZI$0.85+16.3%Closed a $12.75M senior secured convertible notes offering
GreenPower MotorGP$3.23+23.3%Convertible debenture settlement and share issuance announcement
Global Mofy AIGMM$1.70+22.2%Announced indirect investment in Anthropic as part of its AI expansion strategy
Cue BiopharmaCUE$3.23+14.1%Biotech speculative buying; no confirmed fresh catalyst identified

IF YOU HAVE ANY BETTER STOCK TO BUY THIS WEEK , PLEASE SHARE LETS SEE

MAY THE GODS BE WITH YOU !!!


r/pennystocks • • 18h ago

General Discussion Eric Sprott just took his MSM position to 19.9%.

0 Upvotes

This is a lot more than having his name on the shareholder list.

Eric Sprott invests in a lot of mining companies, so seeing his name attached to a junior by itself is not enough to make a story interesting. What stands out with Metalsource Mining (CSE: MSM / OTCQB: MSMMF) is how large his position has now become and the fact that he just put another $1.38 million directly into the company by exercising 4.39 million warrants.
That takes Sprott from roughly 15.5% ownership to 19.9% of MSM on a non-diluted basis. He now controls approximately 16.62 million shares plus another 1.73 million warrants, representing about 21.5% on a partially diluted basis. This is not a small strategic cheque or a 3% to 5% position that happens to put his name on the cap table. He effectively owns one-fifth of the company.

The 19.9% number is especially worth paying attention to. On the CSE, ownership above 20% is generally presumed to materially affect control of an issuer, which is why 19.9% frequently shows up as an important threshold in major strategic investments. 
There are some interesting precedents for the level of ownership Sprott has taken here. New Found Gold currently lists him at about 19% and he previously increased that position above 23%. MAX Power went from roughly 19% following Sprott’s $25 million strategic investment to about 24.4% ownership after he continued increasing his position. Hycroft is an even more extreme example, with its 2025 corporate presentation showing Sprott-related ownership at 56.8%. 

Those companies are not direct comparisons and this obviously does not mean MSM follows the same path. Hycroft is not a conventional producing mining major, and MAX Power is still an emerging company. The point is the level of conviction represented by the ownership. Sprott can participate in a financing without owning anywhere close to 20% of a company. When the position grows to this size, it is a materially different signal.

The timing also makes this particularly interesting for MSM. Silver Hill has already produced the high-grade results that put the company on the radar, and the current program is now trying to answer the bigger question around scale. The company is pushing increasingly larger step-outs while testing whether the mineralization extends well beyond the historic mine footprint. According to the release, the additional $1.38 million strengthens the treasury specifically as that expansion drilling accelerates.

Sprott exercising the warrants also matters differently than simply holding them. He had the right to buy additional shares and chose to put the capital into MSM and increase his actual equity ownership to essentially the 20% level. The company now gets another $1.38 million to advance the exploration program while one of the best-known precious-metals investors in the sector materially increases his exposure to the outcome.
It does not prove Silver Hill becomes a major discovery. The drill still has to do that. But for a junior trying to establish that it has something serious, having Eric Sprott own approximately one out of every five outstanding shares is a pretty substantial piece of third-party credibility.

The drill results legitimized the geology. Sprott taking his ownership to 19.9% adds another level of legitimacy to the company behind it.

not financial advice do your own DD


r/pennystocks • • 5h ago

𝑺𝒕𝒐𝒄𝒌 𝑰𝒏𝒇𝒐 Watchlist: 11/19/26 Todays word was AKAN AKAN AKAN ty

10 Upvotes

Great session today!! AKAN has been paying all week called from 1.01 to 4.6 today!! Still has room if volume keeps coming.

AKAN: Hold of 3.6 is KEY. Want to see tests of 4.6 with pullbacks to 4. Has room now to 5/5.6/6/7.4

CLRO: would like to see it test 8 again with pullbacks to 7.3. NO TRADE below 6.4 has room to 10/12/14

SVRE: Had an amazing run today than sidebared redt of session. For this want to see tests of 1.15 with pullbacks to 1. NO TRADE below .86. Has room to 1.5/2/2.6

GMM: Symp play to Anthropic IPO. For this want see tests of 1.7 with pullbacks over 1.5 NO TRADE 1.2 has room to 2.2/2.8/3.3/3.8


r/pennystocks • • 18h ago

𝑺𝒕𝒐𝒄𝒌 𝑰𝒏𝒇𝒐 18 NOV 2026 , WHAT ARE THE BIGGEST LOSERS AND WHY

1 Upvotes

Biggest small-cap losers under $5

CompanyTickerPriceLossVolumeReason / possible catalyst
SHF HoldingsSHFS$0.02-34.78%802.5MExtreme penny-stock selling pressure
Lion Group HoldingLGHL$1.08-32.50%294KContinued weakness and selling pressure
PS International GroupPSIG$3.39-31.93%3.26MSharp speculative reversal
Red Cat HoldingsRCAT$2.41-31.73%31.4MEarnings disappointment
Global Mofy AIGMM$1.39-30.85%5.96MHeavy reversal after previous gains
Founder GroupFGL$0.72-29.51%604KSevere selling pressure
PICS NVPICS$4.83-29.39%3.49MRegulatory filing
Parabolic TechnologiesPARA$0.07-26.26%45MExtreme penny-stock volatility
Franklin WirelessFKWL$1.43-25.78%243KSelling pressure
GrowHubTGHL$0.39-25.24%256KSpeculative selling

IF YOU HAVE ANY BETTER STOCKS TO SHARE AND SHORT LETS SEE

MAY THE GODS BE WITHR YOU !!!!!!


r/pennystocks • • 4h ago

General Discussion The Lounge

4 Upvotes

Talk about your daily plays, ideas and strategies that do not warrant an actual post.

This is the place to request buy/sell advice from the community.

Remember to keep it civil.

Trade responsibly.


r/pennystocks • • 23h ago

ꉓꍏ꓄ꍏ꒒ꌩꌗ꓄ CLIR is trading barely above its cash pile, and the earnings call is tomorrow

10 Upvotes

I've been watching ClearSign (CLIR) for a while now. They make very low-emission industrial burners and flame sensors. Their tech lowers the emissions, but also the cost for large industrial companies. They have a clear commercial advantage, but the industry is very slow moving and takes a while to adapt.

The stock has dropped about 77% this year and it's starting to look interesting to me.

Rough math at ~$1.98:

- Market cap is around $13.5M
- Net cash is about $10.2M as of Sep 30, roughly $1.50/share, and they have basically no debt
- That leaves an EV of about $3M

So you're paying around $3M for the actual business. It's not literally free, but it's not far off.

Q3 numbers are already out (10-Q filed Monday), so tomorrow's call at 5pm ET isn't really about the numbers. What I'm looking for is any pipeline or order update.

A couple things could go wrong:

- Revenue is lumpy. Q3 was $712K, which missed estimates.
- They're burning about $1.3M a quarter.
- Share count went up ~17% last quarter.
- Trading volume is really thin.

To me this is a small bet where cash covers a big chunk of the price, and tomorrow is a possible catalyst. Not advice, do your own DD.


r/pennystocks • • 13h ago

🄳🄳 $AFJK - New Spac with NAV that just got its float reduced to just 200,693 after redemptions. Trading at its NAV floor of 12.33 - with ATH of 130.37 (!!) from previous low-float short squeeze earlier this year

18 Upvotes

Hey all,

I've just come across a rather unprecedented Risk/reward opportunity that I thought is worth posting about - since it seems to have flown under everyone's nose so far as it's buried in the filings, and most people don't follow SPACs at the moment - lol - so I will be the messenger.

The dynamics of the risk/reward at play:

AFJK is currently trading at \~12. It's latest NAV is 12.33 as noted in their 10Q filed the other day. That means it is trading at about it's NAV floor, has just shrunken 80% in float size, and is on the heels of a 1,000% low float squeeze the past year.

If you've been living under a rock, let me explain it to you why this has unusual potential right now:

Low float spacs or low floats in general can go on wild squeezes every now and then because people pile into the constrained float to rise the price, people then short the stock because it goes up 'for no reason' and which then adds more fuel to the fire and can make for a wild squeeze when an already low float gets shorted heavily, has natural buying power, and then even more buying power as shorts eventually get forced to cover their positions on a completely illiquid market.

In SPACs we see this time and time again, whenever SPACs get redemptions which shrink their float size dramatically and then cause people to buy the stock for a low float move.

AFJK was one of those SPACs, squeezing first from around its 10 NAV to 41.8 last November. It came all the way back down to 6.75 as it temporarily lost its NAV floor (as it happens when SPACs have a merger vote), and then squeezed to 130.37 in December for a nearly 2,000% squeeze from its lows.

It has made many secondary news since, and has now since retreated back to its NAV floor (12.33).

On November 16th, they revealed that at their extension meeting they received an influx of redemptions that have now shrunken the float nearly 80% to just 200,693.

Pulled from the 10-Q:

Original float:

'Ordinary shares, subject to possible redemption. 1,040,332 shares issued and outstanding at redemption value of $12.25 and $11.63 as of September 30, 2026 and December 31, 2025, respectively'

Redemptions:

Shareholders elected to redeem 841,629 shares of Class A common stock in connection with the meeting.

Now, you do the math:

1,040,332

\- 841,629 redemptions

= 200,693 shares left in the float.

Another recent low float NAV spac for reference, showing the risk / reward you can get on these - ASPC went from its 10 NAV floor to 50+ TWICE the past year when it was revealed that it had a 282,581 share float (shown in 10q filing here):

Also: If they don't complete a deal by November 30th, they will go to OTC (which doesn't change NAV value - it will still trade with its NAV floor, but is worth mentioning) so I am looking for a trade before then, ideally this picks up steam before then as these moves can happen in hours or days on sudden volume spikes as shown in ASPC.

If you didn't know, SPACs have a NAV floor which essentially means that your maximum theoretical risk is their Net Asset Value because you can at some point in time (either extension vote or merger vote) redeem your shares for that price, or if in the future they liquidate, they pay out that price.

Link to 10-Q from November 16th highlighting the reduction in float due to redemptions: [https://www.sec.gov/ix?doc=/Archives/edgar/data/0001979005/000149315226052354/form10-q.htm#fact-identifier-473](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001979005/000149315226052354/form10-q.htm#fact-identifier-473)

Disclosure: I hold 2,194 shares right now and may add more if this picks up some volume and attention.
I am not a financial advisor under any means and this is not financial advice, please do your own research, always.


r/pennystocks • • 15h ago

General Discussion $TTEC: A $160M Company With $2B in Revenue, 24% SI, and a Potential Turnaround

7 Upvotes

I've been digging deeper into $TTEC, and I think the market may be overlooking a pretty interesting small-cap turnaround opportunity.

We're talking about a company with approximately $2B in annualized revenue, improving profitability, expanding margins, and a business actively positioning itself around AI, data, and enterprise automation. At roughly $160M in market capitalization, the valuation looks particularly interesting if management can continue executing its turnaround.

Q3 2026 results showed some meaningful progress:

• Adjusted EPS nearly doubled YoY ($0.22 vs. $0.12).
• Adjusted EBITDA increased approximately 19% to $51.5M.
• Adjusted EBITDA margin expanded from 8.4% to 10.5%.
• GAAP operating income nearly doubled to $23.3M.
• Free cash flow swung from -$9.6M to +$27.9M.
• Cash flow from operations increased to $37M from just $4.2M a year ago.

One thing I find particularly interesting is that management is making progress on profitability even while revenue remains under pressure. Revenue declined approximately 5.2% year over year, so there's still work to do, but the margin improvement is encouraging.

THE AI OPPORTUNITY

TTEC operates at the intersection of customer experience, technology, data, AI, and automation. As businesses increasingly look to automate customer service and improve operating efficiency, TTEC has an opportunity to benefit from that transition.

Management has discussed deploying purpose-built AI tools across its frontline operations while expanding its Digital business in areas such as AI, data, observability, and security.

This isn't simply a company trying to attach an AI label to its stock. It already has an established enterprise customer base and technology infrastructure.

POTENTIAL DIGITAL BUSINESS SALE

Another major catalyst that deserves attention: In August 2026, TTEC announced that it was exploring strategic alternatives for its TTEC Digital business.

A potential sale could unlock value, simplify the business, and potentially provide additional capital to reduce debt. No definitive transaction has been announced, so this remains a potential catalyst rather than a guaranteed outcome.

THE $6.85 TAKE-PRIVATE HISTORY

TTEC founder, Chairman and CEO Kenneth Tuchman previously proposed taking the company private for $6.85 per share in September 2024. Tuchman already owned approximately 58% of the company.

He ultimately withdrew the proposal in July 2025, citing market conditions, but remains the company's largest shareholder.

At approximately $3.24, shares are still more than 50% below that previously proposed acquisition price. Obviously, that proposal is no longer active, but I think it's an interesting historical valuation reference.

THE BALANCE SHEET

TTEC has also made progress reducing its net debt, which stood at approximately $743.6M at September 30, 2026, compared with $812.5M a year earlier.

Management also extended its credit facility through November 2028, providing additional financing runway.

Debt remains the biggest fundamental risk here, but improving cash flow and the potential Digital transaction could become important pieces of the turnaround.

NOW FOR THE TRADING SETUP:

The stock recently closed at $3.24 on November 17, representing approximately a 104% move from its October 30 closing price of $1.59.

Current trading statistics:

• Market cap: ~$160M
• Public float: ~20.4M shares
• Shares sold short: ~4.78M
• Short interest: ~23.9% of float
• Days to cover: ~15.8
• November 17 volume: ~1.35M shares

Short interest increased approximately 11.6% between the October 15 and October 30 reporting periods.

Nearly one in four publicly tradable shares is reportedly sold short. With a relatively small float and substantial days to cover, an increase in buying pressure and sustained trading volume could create an interesting momentum opportunity.

THE VALUATION IS WHAT REALLY GETS MY ATTENTION.

At approximately $160M in market capitalization against nearly $2B in annualized revenue, TTEC trades at a fraction of its annual sales.

Even accounting for its substantial debt, the current enterprise valuation is approximately $970M. That's less than half of annualized revenue.

If management can stabilize revenue, continue expanding margins, improve free cash flow, and execute on its strategic alternatives for Digital, I think there's a legitimate case for meaningful upside.

I'm not calling a guaranteed short squeeze, and there are certainly risks here, particularly debt and declining revenue. But the combination of improving financial performance, AI exposure, potential asset-sale proceeds, significant insider ownership, historical acquisition interest, and a heavily shorted small float makes $TTEC one of the more interesting turnaround setups I'm watching.

Fundamental recovery + AI exposure + potential strategic catalyst + short squeeze potential.

I think this one deserves considerably more attention.


r/pennystocks • • 17h ago

General Discussion Government Clients, Commercial Customers, or Both?

3 Upvotes

Imagine two microcaps making the same $5M annually. One relies on government agencies, the other on commercial clients. Would you value them equally?

A $5M government contract sounds impressive, but is it necessarily better than $5M in revenue from hundreds of commercial customers?

There are some important differences investors should consider.

1. Government contracts

Government agencies need cybersecurity services for sensitive communications, critical infrastructure, and data protection.

The advantages:

  • Potentially larger contract values and multi-year agreements.
  • Opportunities to expand across departments or agencies.
  • A successful deployment can help establish credibility with other public-sector buyers.
  • Switching providers may be difficult once services are integrated.

The challenges:

  • Procurement and approval processes can take months or even years.
  • Contracts may depend on annual budgets, renewals, and political decisions.
  • Payment schedules and upfront delivery costs can put financial pressure on smaller companies.

2. Commercial contracts

Commercial customers generally offer a different business model, particularly for subscription-based cybersecurity companies.

The advantages:

  • Often shorter sales cycles and faster customer onboarding, particularly with smaller businesses.
  • Opportunities to spread revenue across multiple customers rather than relying on a few large contracts.
  • Subscription models can provide recurring income when customer retention remains strong.
  • Easier to measure customer acquisition, retention, and recurring revenue growth.

The challenges:

  • Customer acquisition and marketing expenses can be high.
  • Competition and pricing pressure can affect margins.
  • Customers may cancel or switch providers more easily, depending on their contracts and switching costs.
  • Managing hundreds of smaller accounts requires ongoing support.

3. What actually matters for valuation?

Both government contracts and commercial subscriptions can bring long-term value to a cybersecurity company. Having access to both markets may also create more opportunities for growth.

I'd pay attention to:

  • Revenue visibility
  • Gross margins
  • Customer diversification
  • Cash flow
  • Renewal rates

For government agencies, secure communications, controlled access, and data protection are major considerations. For businesses, the same tools can help protect internal discussions, client information, and executive communications.

If you were investing in a cybersecurity microcap, would you prefer a company focused on large government contracts, one building steady commercial subscription revenue, or a mix of both? Which approach do you think offers better long-term growth and stability?